Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital
| Autor: | M J, Pérez-Granda, P, Catalán, P, Muñoz, T, Aldámiz, J C, Barrios, C, Ramírez, R, García-Martínez, M V, Villalba, L, Puente, E, Bouza |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Revista Española de Quimioterapia. 36:45-51 |
| ISSN: | 1988-9518 0214-3429 |
| DOI: | 10.37201/req/068.2022 |
| Popis: | Purpose. To determine the prevalence of CMV reactivation in a population admitted for severe COVID-19 to a general hospital. Methods. Point prevalence study in all hospitalized patients with severe COVID-19 (admitted either to general wards or ICU). Determination of the presence of CMV DNA in circulating blood. COVID-19 was confirmed in patients with compatible clinical manifestations, usually with pneumonia and a positive nasopharyngeal PCR test. Results. We included 140 hospitalized patients with COVID-19 who consented to participate. A total of 16 patients (11.42%), had circulating CMV-DNA in peripheral blood at the time of the study. Patients with positive CMV viral load were mainly ICU patients (11/37 -29,7%) and only 5/103 cases (4,85%) were hospitalized into general wards. The accumulated doses of corticosteroids (prednisone equivalents) in the study day were (median and IQR) 987.50 mg (396.87-2,454.68) and 187.50 mg (75.00-818.12) respectively in CMV positive and negative patients (p < 0.001). A significant proportion of CMV positive patients were discovered because of the study and were clinically unsuspected by their physicians. The coinfected COVID-CMV positive population had a higher risk of accumulated secondary nosocomially-acquired infections and a worse prognosis. Conclusion. CMV reactivation should be systematically searched in patients in COVID-19 cases admitted to the ICU. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|